文献速递神经肿瘤

血浆游离RNA作为胶质瘤生物标志物的初步研究

The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study.
PubMed 文献 · Acta Neurochir (Wien) · 2021-10-13

该初步研究采集20例胶质瘤患者术前血样,分析血浆游离信使RNA与肿瘤组织RNA表达谱。发现BCL2L1、GZMB、HLA-A等基因在胶质瘤患者中显著高表达,且GZMB和HLA-A在高分级胶质瘤中更高;血浆与肿瘤组织及TCGA来源RNA表达变化呈正相关。

要点

  • 血浆游离RNA表达谱与胶质瘤组织RNA及TCGA数据呈正相关
  • GZMB和HLA-A基因在高分级胶质瘤患者中显著高表达
  • CSF3基因表达变化与影像学肿瘤负荷呈正相关

核心结论

  • 不同级别胶质瘤患者间存在癌症炎症与免疫交叉相关基因的显著差异表达。
  • 血浆与肿瘤样本转录组谱呈正相关,且与TCGA胶质瘤来源RNA相关。

研究设计与样本

  • 研究纳入20例胶质瘤患者,于肿瘤切除术前采集血样。
  • 提取并分析血浆游离信使RNA与胶质瘤组织RNA表达谱。

主要发现

  • BCL2L1、GZMB、HLA-A、IRF1、MYD88、TLR2、TP53基因在胶质瘤患者中显著高表达(p < 0.001,对比对照组)。
  • GZMB和HLA-A基因在高分级胶质瘤患者中显著高表达(p < 0.001,对比低分级胶质瘤患者)。
  • BCL2L1基因表达变化倍数在高分级胶质瘤患者中更高(p = 0.022,对比低分级胶质瘤患者)。
  • 血浆与胶质瘤组织差异表达基因变化倍数呈正相关(Spearman r = 0.6344,n = 14,p = 0.017)。
  • 血浆差异表达基因变化倍数与TCGA胶质瘤RNA样本平均FPKM呈正相关(Spearman r = 0.4614,n = 19,p < 0.05)。

临床怎么用

  • 血浆游离RNA或可作为胶质瘤非侵入性辅助生物标志物,但需进一步验证。
  • 检测BCL2L1、GZMB、HLA-A等基因表达变化可能有助于区分胶质瘤级别。

局限性

  • 本研究为初步研究,样本量小(20例)。
  • 结论需在更大队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Research into the potential utility of plasma-derived circulating cell-free nucleic acids as non-invasive adjuncts to radiological imaging have been occasioned by the invasive nature of brain tumour biopsy. The objective of this study was to determine whether significant differences exist in the plasma transcriptomic profile of glioma patients relative to differences in their tumour characteristics, and also whether any observed differences were representative of synchronously obtained glioma samples and TCGA glioma-derived RNA. METHODS: Blood samples were collected from twenty glioma patients prior to tumour resection. Plasma ccfmRNAs and glioma-derived RNA were extracted and profiled. RESULTS: BCL2L1, GZMB, HLA-A, IRF1, MYD88, TLR2, and TP53 genes were significantly over-expressed in glioma patients (p < 0.001, versus control). GZMB and HLA-A genes were significantly over-expressed in high-grade glioma patients (p < 0.001, versus low-grade glioma patients). Moreover, the fold change of the BCL2L1 gene was observed to be higher in patients with high-grade glioma (p = 0.022, versus low-grade glioma patients). There was positive correlation between the magnitude of fold change of differentially expressed genes in plasma- and glioma-derived RNA (Spearman r = 0.6344, n = 14, p = 0.017), and with the mean FPKM in TCGA glioma-derived RNA samples (Spearman r = 0.4614, n = 19, p < 0.05). There was positive correlation between glioma radiographic tumour burden and the magnitude of fold change of the CSF3 gene (r = 0.9813, n = 20, p < 0.001). CONCLUSION: We identified significant differential expression of genes involved in cancer inflammation and immunity crosstalk among patients with different glioma grades, and there was positive correlation between their transcriptomic profile in plasma and tumour samples, and with TCGA glioma-derived RNA.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Ita MI, Wang JH, Toulouse A, et al. The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma: a pilot study. Acta Neurochir (Wien). 2021. PMID: 34643804. doi:10.1007/s00701-021-05014-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。